Abstract
Summary. Haemophilia, an ancient disease, now has sophisticated methods for diagnosis and treatment. The genetically missing factors can now be supplied by fractionation of human-derived (HD) plasma or with recombinant technology (r). Making therapeutic choices is complicated by past transfusion-transmitted diseases. HD and r products now have similar safety profiles. Several diseases have only HD products for treatment. These products remain important in our treatment armamentarium.
| Original language | English |
|---|---|
| Pages (from-to) | 1-2 |
| Number of pages | 2 |
| Journal | Haemophilia |
| Volume | 13 |
| Issue number | SUPPL. 5 |
| DOIs | |
| State | Published - Dec 2007 |
Keywords
- Haemophilia
- Inhibitors
- Recombinant and human-derived factors
- Von Willebrand disease